(Q36165319)

12 August 2017

6 references

3 April 2019

27 September 2019

12 October 2019

18 October 2019

27 November 2019

13 December 2019

B cell non-Hodgkin's lymphoma: rituximab safety experience (English)

1 reference

12 August 2017

6 references

3 April 2019

27 September 2019

12 October 2019

18 October 2019

27 November 2019

13 December 2019

1 reference

27 September 2019

1 reference

12 October 2019

hemic and immune systems

1 reference

18 October 2019

1 reference

27 November 2019

1 reference

13 December 2019

1 reference

Ann Mohrbacher

1

1 reference

12 August 2017

18 May 2005

7 references

Arthritis Research and Therapy

12 August 2017

3 April 2019

27 September 2019

12 October 2019

18 October 2019

27 November 2019

13 December 2019

7 references

12 August 2017

3 April 2019

27 September 2019

12 October 2019

18 October 2019

27 November 2019

13 December 2019

7 Suppl 3

1 reference

12 August 2017

S19-25

1 reference

https://scigraph.springernature.com/pub.10.1186/ar1739

12 August 2017

0 references

cites work

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833973

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

23 September 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2833973

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

23 September 2018

1 reference

12 December 2020

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

12 December 2020

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

1 reference

12 December 2020

Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma

1 reference

12 December 2020

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

12 December 2020

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab

1 reference

12 December 2020

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study

1 reference

12 December 2020

Rituximab in indolent lymphoma: the single-agent pivotal trial

1 reference

12 December 2020

Identifiers

DOI

10.1186/AR1739

1 reference

PMC publication ID

2833973

Dimensions Publication ID

12 August 2017

0 references

1 reference

PMC publication ID

2833973

12 August 2017

PubMed publication ID

15960818

1 reference

PMC publication ID

2833973